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Part A: Preface 
 
My Role 
 
I completed this project while employed full time as a data manager for the 
Gastrointestinal surgery department at Royal North Shore Hospital in St Leonards, 
between March 2013 and September 2013. This project was supervised by Dr Patrick 
Kelly (statistical supervisor), and Dr Thomas Hugh, Head of UGI surgical 
department. 
 
After speaking with clinical staff in our department, I decided to use the data that I 
work with on a day to day basis to evaluate predictors of survival for patients with 
colorectal liver metastases following hepatic surgery, with an emphasis on the timing 
of hepatic metastases. The intention was to increase our knowledge on survival 
patterns so that the best treatment options are selected for our patients, and to publish 
the results as a journal article. 
 
I completed this project independently, seeking statistical advice as required. My 
tasks included but were not limited to data collection, data entry, data management, 
data extraction, coding, writing Stata programs, statistical analysis and report writing. 
 
 
Reflections on Learning 
 
Communication 
 
This project helped me to develop my communication skills in both completing the 
project and communicating the results. During the course of the project I was required 
to communicate to staff internal and external to our department to negotiate the 
exchange of data in a timely manner.  This would involve communicating the purpose 
of the project as well as directions on data requirements such as extracting data from 
histopathology databases. 
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This project also required myself to communicate complex statistical results to 
clinicians both verbally and in writing. When communicating ideas with clinicians it 
was a challenge to ensure statistical accuracy while still maintaining clinical 
relevance. 
 
 
Work Patterns/Planning 
 
Working as a data manager one of my main tasks is the maintenance of a liver 
database where the data for this project was extracted. Being involved in every step of 
data collection, data entry and data management tasks, I am aware of the strengths and 
limitations of the data for this project. Knowing the existing gaps in the database as 
well as reliability issues with some variables, I was required to be organised and plan 
ahead for the required extra data collection necessary for the project.  
 
After reviewing the literature I became aware of more gaps in our departments liver 
database, especially with the primary resection data. Perhaps not quite gaps in our 
data, but data that would have been sourced from the colorectal department if they 
had a data manager and/or reliable and complete database. Without this vital source of 
data I was required to look for administration assistance within our department to 
obtain almost 300 primary histopathology reports to be reviewed by myself.  
 
While searching for missing data I had to drop variables from the analysis due to large 
amounts of missing data and after determining that collecting this data would not be 
feasible within the required timeframe. Towards the end of this project I had to shift 
my focus away from obtaining the latest follow-up to fine tuning the analysis. While I 
made every effort to obtain the latest follow-up by reading the latest consultation 
letters in our surgeon’s databases, requesting letters from other clinician’s databases, 
contacting patients and reviewing patient’s hospital notes, I soon became aware that I 
would need to set a timeframe at which point I would cease updating follow-up.  
 
 
 
 
 4 
 
Statistical Principles, methods and computing 
 
This project examined predictors of overall survival and disease free survival for 
patients with colorectal liver metastases following hepatic resection with an emphasis 
on the timing of hepatic metastases. These two outcomes were examined by 
constructing Cox proportional hazard models using variables identified by the 
purposeful selection of covariates method.  
 
This project gave me insight into the importance of having organised do.files in Stata 
for complex statistical analysis. Working on several studies concurrently I soon 
realised the importance of taking notes within do.files, so that i could resume working 
on the project after being distracted by other projects and routine tasks required by my 
job. Throughout the course of the project, different decisions were made which 
required alterations to the do.file. Having an organised do.file allowed me to easily 
know where to change the code to obtain the results required.   
 
 
Teamwork 
 
I worked on this project under the supervision of Dr Patrick Kelly (statistics) and Dr 
Thomas Hugh. I met every two weeks with Dr Kelly to discuss my progression in the 
project and to ensure that my statistical methods were sound. I frequently met with Dr 
Hugh to discuss the clinical content for the project.  
 
 
Ethical considerations 
 
 No ethical considerations further to those already employed in my role at the UGI 
surgery department have been necessary. Patients were de-identified using IDs prior 
to analysis and data was stored securely in a password protected laptop. No 
information presented in this WPP would allow the identification of patients. 
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Location and dates:  Royal North Shore Hospital, Sydney, NSW, March‐September 
2013 
Context:  This project was completed while employed full time as the 
data manager for the gastrointestinal surgical department. 
Contribution of student:  Martin completed all data collection, data management, review 
of literature, design of study, statistical code, analyses, journal 
writing and presentation of results.  
Statistical issues involved:   Kaplan‐Meier survival analyses 
 Cox Proportional Hazards Regression 
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Abstract 
 
Objective 
 
The aim of this study was to evaluate the long-term outcome of patients with 
synchronous and metachronous colorectal liver metastases (CLRM) with an emphasis 
on prognostic factors for survival. 
 
Methods 
 
Between 1999 and March 2013, 276 patients with colorectal liver metastases 
underwent hepatic resection. These patients were identified in a prospectively 
collected database and analysed retrospectively. Multivariate Cox proportional 
hazards were used to obtain adjusted hazard ratios for synchronous versus 
metachronous colorectal liver metastases.  
 
Results 
 
The timing of liver metastases was synchronous with the primary in 138 patients 
(50%). Compared with the metachronous group (n=138), patients with synchronous 
metastases were younger, were twice as likely to have bilateral disease, were more 
likely to have three or more hepatic tumours and had four times the risk of having 
poorly differentiated tumours. There were a total 132 deaths with 826 years at risk. 
The median overall survival for the whole cohort was 44.5 months with an overall 
five year survival of 41%. Multivariate analysis for overall survival found weak 
statistical evidence (HR= 1.42, 95% CI=0.98-2.06,  p=0.06) of a difference in survival 
between the synchronous and metachronous patients, with synchronous patients 
having a poorer overall survival. The analysis for disease free survival found 
synchronous CRLM to be a significant predictor of poorer disease free survival (HR= 
1.47, 95% CI=1.08-2.00 , p=0.01) 
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Conclusions 
 
This study found weak evidence of a difference in overall survival between patients 
with metachronous and synchronous liver metastases. A difference was found in 
disease free survival with patients with synchronous liver metastases being 47% more 
likely to develop recurrence in the post hepatic surgery period. 
 
 
 
Keywords: hepatectomy, colorectal, liver metastases, synchronous, metachronous 
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Introduction 
 
Colorectal cancer (CRC) in the second most common cancer in Australia with 
approximately 15,000 new diagnoses each year. It is the second leading cause of 
cancer deaths after lung cancer with 3,982 deaths in 20101. Approximately two thirds 
of all patients with CRC develop distant metastases and the liver being the most 
common site (70%) is frequently the only site affected2, 3. Colorectal liver metastases 
(CRLM) are defined as being either synchronous or metachronous with the diagnosis 
of the primary tumour. However, the exact definition of these categories is not clear 
with differences reported depending on where metastases were detected by pre-
operative screening or during resection of the primary tumour and at specific times of 
the initial diagnosis of CRC4, 5. Depending on the definition, the incidence of 
synchronous metastases has been reported to range between 23% - 50%. Some groups 
suggest that synchronous metastases have a worse prognosis compared with 
metachronous metastases2-16. However, the data are heterogeneous and the findings 
are often conflicting. Therefore, we conducted a retrospective review of prospectively 
collected surgical data on patients who have undergone resection of CRLM, to 
investigate predictors of overall and disease free survival, with an emphasis on 
synchronous vs metachronous. 
 
 
Patients and Methods 
 
Consecutive patients with CRLM who underwent hepatic resection in the Northern 
HPB surgical unit during a 15 year period from December 1999 to March 2013 were 
analysed. A total of 357 patients underwent hepatic resection with curative intent, 
including 188 patients with synchronous liver metastases (SCRLM) and 169 patients 
with metachronous liver metastases (MCRLM). Patients with repeat hepatic 
resections were excluded from the analysis. Data from the database are summarised in 
Table 1. 
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Data collection and definitions 
 
Data were collected and maintained prospectively and stored in a secure database 
within the HPB surgical unit at RNSH. Data analysed included demographic, clinical, 
radiological and pathological characteristics. These were analysed retrospectively. 
 
Preoperative data collected included details of the primary colorectal cancer 
(histopathology, primary site and Dukes classification), any complications following 
primary surgery, the use of pre-operative chemotherapy and the timing of diagnosis of 
hepatic recurrence. Synchronous metastases were defined as those detected before the 
primary resection, intra-operatively at the time of primary tumour surgery or by 
imaging studies within 12 months after the primary surgery. 
 
Operative data collected included operative time, operation type (using the Brisbane 
terminology17) and the estimated blood loss volume in mm (categorised into three 
groups <200mm, 200-399mm and >400mm). Minor resections were defined as less 
than three Couinaud segments resected, while major resections were defined as equal 
to or greater than three segments resected. 
 
Postoperative data analysed included histopathology findings tumour site (grouped as 
unilateral vs bilateral/central), size of the largest tumour diameter (categorised into 
four groups spaced 20mm), number of tumours (categorised into three groups 1, 2-3 
and >3 tumours), resection margin (categorised into three groups <1mm, 1-10mm and 
>10mm; where <1mm includes involved margins), and tumour differentiation 
(categorised into two groups well/moderate vs poor) based on the part of poorest 
differentiation in the tumour. Other postoperative data collected included the length of 
hospital stay in days (categorised into four groups 0-6, 7-10 and >10 days) and 
complications following surgery (categorised into two groups none/minor vs major). 
For the final survival analysis peri-operative mortality up to 30 days was excluded. 
Peri-operative mortality was defined as deaths during the same admission or within 30 
days of surgery. 
 
Overall survival was calculated from the time of hepatic surgery to the date of death 
(all cause mortalities). No patients in this analysis were censored at death. Those alive 
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at the end of the follow-up period were classified as censored and contributed their 
time interval from their hepatic operation date to the end of follow-up to the survival 
analysis. Disease free survival was calculated from the time of hepatic surgery till the 
date of first recurrence (local or otherwise). Patients were censored in a similar 
fashion as those censored in the overall survival analysis. Survival times were 
recorded in months. 
 
Preoperative work-up and operative technique 
 
All patients underwent a baseline pre-operative assessment including liver function 
tests (LFTs), coagulation studies, serum CEA and Ca19-9 levels and a fine-cut, multi-
phase computed tomography (CT) scan of the abdomen and thorax. A positron 
emission tomography (PET) scan was also performed to exclude extra-hepatic disease 
but only from January 2004. All cases were discussed at a multi-disciplinary group 
meeting prior to liver resection. Operative criteria included the likelihood of achieving 
and R0 resection (microscopically clear margin) along with preservation of vascular 
inflow and outflow and an adequate liver remnant volume. Patients with limited extra-
hepatic, intra-abdominal disease (eg. Porta-hepatis lymph node involvement or 
isolated upper quadrant peritoneal disease) were not excluded from resection. Liver 
transection was performed using the Cavitron Ultrasonic Aspirator (CUSA) dissection 
device (Integra, New Jersey) under low CVP conditions with intermittent inflow 
occlusion. 
 
The follow-up regime included six monthly clinical evaluations, serum tumour 
markers and annual CT scans of the thorax and abdomen. 
 
 
Statistical analysis 
 
Descriptive statistics were reported using means (standard deviation) and medians 
(interquartile ranges) depending on their distributions. The comparison of patient 
characteristics between patients with synchronous and metachronous metastases was 
done using Wilcoxon’s rank sum test, Students t test and χ2-test where appropriate.  
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Univariate analysis was performed using the log-rank test to identify potentially 
significant variables for the multivariate model. Multivariate analysis was performed 
using the purposeful selection of covariates method proposed by Hosmer, Lemeshow 
and May18, with  variables initially entered into the model if the univariate p<0.25. 
Variables were removed one at a time, starting with least significant and remained in 
model if p<0.05 or were confounded with synchronous/metachronous, indicated by 
more than 10% change in HR. At the end of the process, excluded variables were also 
entered into the model to check for their significance and confounding.  Due to 
evidence of non-proportional hazards for primary site the model was stratified at 3.5 
years after hepatic surgery. The final model was assessed for validity of proportional 
hazards assumption using Shoenfeld residuals and goodness of fit using Cox-Snell 
residuals. Data management and statistical analysis were performed using Intercooled 
Stata version 12.1 for windows (Statacorp TX USA). 
 
Results 
 
During the period January 1999 – March 2013, 315 patients underwent resection for 
CRLM from which 36 patients went on to have a secondary resection, and three 
patients had a third resection. Excluding all patients who went onto have repeat 
hepatic resections, 276 patients were identified for inclusion in this study. The mean 
age in the cohort was 64 years (SD=11) and males accounted for 62% of the 
population. The timing of the liver metastases was synchronous with the primary in 
138 patients (50%). Compared with the metachronous group (n=138), patients with 
synchronous metastases were younger (p<0.01), were twice as likely to have bilateral 
disease (p<0.01), were more likely to have three or more hepatic tumours (p<0.01) 
and had four times the risk of having a poorly differentiated tumours (p=<0.01). All 
other comparisons between synchronous and metachronous metastases were non-
significant as shown in Table 1. The median patient follow-up for all patients was 26 
months (IQR: 12-49 months). At the time of analysis 54 (20%) patients had been 
observed for at least five years. 
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Primary resection 
 
The colon was the primary site in 186 patients (67%) with the majority of patients 
(64%) classified with Dukes C tumour. Primary surgery resection complications were 
experienced in only 10% of patients. In the majority of cases, the primary tumour was 
resected prior to the liver resection (87%) while 7% of patients had their primary and 
liver metastases resected simultaneously and only 7% had their liver resection 
performed before the primary tumour was resected. 
 
Hepatic resection 
 
The majority of patients (69%) had pre-operative chemotherapy prior to their liver 
resection. All resections were performed by one of two surgeons of which 221 (80%) 
were performed by TH and 55 (20%) were performed by JS. These included 67 (24%) 
right hepatectomies, 16 (6%) left hepatectomies, 32 (12%) extended right 
hepatectomies, 13 (5%) extended left hepatectomies, 71(26%) segmental resections 
and 34 (12%) wedge resections. 39(14%) patients had multiple hepatic resections 
performed simultaneously. In this study there were 168 patients (61%) major 
resections with a median operative time for the whole cohort of 180mins (IQR: 150-
240). The median estimated blood loss for all resections was 200mL (IQR: 100–
400mL). The tumour site was unilateral in 190 patients (69%) with 130 patients 
(47%) presenting with a solitary tumour, 95 (34%) with two or three tumours, and 51 
(18%) with more than three tumours. The median tumour measurement was 32mm 
(IQR: 20-55mm) where 68% had a R0 (≥1mm) resection and 18% of patients had an 
R1 resection. The majority of tumours were moderately differentiated (73%) with 41 
missing differentiations (15%) due to lack of reporting in the histopathology report. 
The median length of stay for the whole cohort was eight nights (IQR: 7-10 nights). 
 
Post-operative morbidity occurred in 111 (41%) patients but, of these 65 (24%) 
patients experienced a minor complication and 46 (17%) patients experienced a major 
complication. The overall mortality was 2% (five cases). Three patients developed 
liver failure leading to death, one patient had a bile leak and intra-abdominal 
collection, while one other patient had a bowel obstruction from an incarcerated 
hernia resulting in death.  
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Post-hepatic surgery recurrence occurred in 158 (57%) patients with the most 
common site of recurrence being the liver (48%) followed by pulmonary (33%), other 
sites (10%) and intra-abdominal (10%). Multiple sites of synchronous recurrence 
were observed in 18% of the cohort with the most common combination being intra-
hepatic and pulmonary (49%). The overall median time to recurrence was eight 
months (IQR: 5-17), with a median of seven months to recurrence for synchronous 
patients and 11 months for metachronous patients (p=0.02). The frequency to 
recurrence of any type was 65% in the synchronous group and 52% in the 
metachronous group (p=0.09). 
 
Survival 
 
The median overall survival for the whole cohort was 44.5 months (95% CI: 35.6-
56.2) with an overall five year survival of 41% (95% CI: 34-48%). There were 132 
deaths in the cohort with 9912 months at risk. The median disease free survival was 
15.6 months (95% CI: 12.5-19.8) with a 5 year disease free survival of 28% (95% CI: 
22-34%). There were 181 deaths or recurrence in the cohort with 7068 months at risk. 
 
Univariate analysis 
 
Univariate analysis for overall and disease free survival is summarised in Table 2. 
This found that Dukes C primary disease, synchronous CRLM, major liver resections, 
blood loss ≥400mL, length of operation ≥240min, bilateral/central site, tumour size 
≥40mm, tumour number >1, poor liver metastases differentiation, margins <10mm, 
length of stay ≥11 days and post-operative complications were all predictors of worse 
overall survival, compared to their respective base categories. 
 
This analysis found that Dukes C primary tumour, synchronous CRLM, major liver 
resections, pre-operative chemotherapy, blood loss ≥400mL, length of operation 
≥240min, bilateral/central site, tumour size ≥40mm, tumour number >1, poor liver 
metastases differentiation, margins <10mm and length of stay ≥11 days were all 
predictors of worse disease free survival, compared to their respective base categories. 
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Multivariate analysis 
 
Multivariate analysis for overall and disease free survival is summarised in Table 3. 
Multivariate analysis found age ≥65 years, pre-operative chemotherapy, tumour size 
≥40mm, tumour number >1, rectal primary site 3.5 years post hepatectomy and length 
of stay ≥11 days to be significant predictors of poorer overall survival (Note base 
categories in Table 3). No difference in survival was found between colonic and rectal 
primary sites prior to 3.5 post hepatectomy. There was only weak statistical evidence 
(p=0.06) of a difference in survival between the synchronous and metachronous 
groups (Figure 1). 
 
Similarly the multivariate analysis for disease free survival found synchronous CRLM 
(Table 4), pre-operative chemotherapy, tumour size ≥40mm, tumour number >1 and 
length of stay ≥11 days to be significant predictors of poorer disease free survival 
(Note base categories in Table 3).. However, patients with synchronous liver 
metastases were found to be 47% (95% CI: 8%-100%; p =0.01) more likely to 
develop recurrence in the post hepatic surgery period (Figure 2). 
 
 
 
Discussion 
 
The aim of this study was to identify predictors of overall and disease free survival for 
patients with CRLM, with an emphasis on the timing of the diagnosis of hepatic 
disease compared with the primary disease. Although there was only weak evidence 
(p=0.06) of a difference in overall survival between patients with synchronous and 
metachronous liver metastases, this study found that patients with synchronous liver 
metastases were found to be 47% more likely of disease progression (p=0.01).  
The median overall survival of 45 months and a 5 year survival of 41% was 
comparable to other large series2, 7-12, 14-16, 19-21.  Multivariate analysis found that age 
≥65 years, pre-operative chemotherapy, tumour size >40mm, tumour number>1, 
rectal primary site 3.5 years post hepatectomy and length of stay ≥11 days were 
predictors of poorer overall survival, compared to their respective base categories. 
 16 
 
Similarly the median disease free survival of 16 months and a 5 year disease free 
survival of 28% was also found to be within the range found in the literature14, 20, 21. 
Most recurrences were identified during the first nine months post-hepatic surgery 
and the liver the most common site of recurrence (48%). Multivariate analysis found 
that synchronous metastases, tumour size >40mm, tumour number >1 and length of 
stay >11 days were predictors of poorer disease free survival, compared to their 
respective base categories. 
 
There have been a number of previous studies that have examined survival following 
hepatic resection of CRLM. Most studies agree that tumour size, tumour numbers, 
elevated CEA, positive resection margin, and extra-hepatic disease, are significant 
predictors of worse overall survival, however timing of diagnosis of hepatic disease 
from primary is controversial.  It is conceivable that synchronous disease is a worse 
biologically behaving tumour. If this is true then this questions the role of liver 
surgery for the synchronous patients and raises the issue of whether systemic 
treatment such as chemotherapy is more important than regional liver surgery. 
 
In a large series from Memorial Sloan-Kettering Cancer Centre, Fong et al.16 similarly 
showed that number and size of hepatic tumours were predictors of worse overall 
survival. In addition they found that timing from primary to metastases <12 months, a 
positive resection margin, extra-hepatic disease, node-positive primary disease and 
CEA >200ng/ml were all predictors of poor long term survival. Other studies such as 
Nordlinger et al.13, Rees et al. 19 and Ueno et al. 12 had similar findings, with the 
addition of Age and Primary tumour differentiation being significant in Nordlinger et 
al. and Rees et al. respectively. In contrast, Rees et al. failed to find timing from 
primary to metastases to be a significant predictor of survival.  
 
Cummings et al22 conducted a population based study and found that 5 year survival 
rates were higher among patients who presented initially with disease in stages I 
through III (metachronous) than those with synchronous metastases (43.3% vs 22.9%; 
P<0.01). The survival period however was calculated from the time of primary 
diagnosis rather than the time of hepatic surgery as more commonly described in the 
literature and the current study. This study design, as pointed out by Wang et al3, 
creates a bias, whereby future observations are being used to model future risk. This 
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design breaks the first rule of thumb proposed by Wolfe et al23, that patient 
characteristics that are measured during follow-up should not be used to compute a 
fixed covariate for a proportional hazards model since it almost always obscures the 
interpretation of a casual mechanism.  
 
A similar finding to the current study was found by Tsai et al14, who conducted a 
retrospective review of 155 patients who underwent curative hepatic resection for 
CRLM and found that disease free survival in the metachronous group was superior to 
that in the synchronous group. Similar to the current study, no difference was found 
for overall survival potentially due to the low numbers to detect a significant 
difference. 
 
A possible explanation for the inconsistency of agreement that timing is a significant 
predictor of survival could be the variability of screening programs around the world. 
More stringent screening after primary surgery could help identify synchronous 
disease and lower the risk of misclassification of metachronous disease which may be 
diluting any true difference. A similar argument described by Tan et al10 is detection 
bias inherent in patients with metachronous disease as they would be more likely to 
have regular screening post primary resection allowing earlier detection of metastases, 
which is not possible for patients presenting for the first time with synchronous 
disease. Another explanation could be the lack of agreement of the exact definition of 
metachronous disease with reports varying from detection of metastases >6 months to 
>24 months post primary resection or from primary diagnosis. Another problem is 
lack of consistency of the definition of extra-hepatic disease in the literature. The 
literature fails to document if routine PET scans were carried out and fails to describe 
a consistent workup.  It may not be surprising that metachronous patients have a 
better prognosis because these patients are a highly selected group, meaning that those 
who develop intra-abdominal or pulmonary recurrence in the post primary surgery 
surveillance period never get to see a liver surgeon especially if they fail to respond to 
systemic therapy. A study of 159 patients by Sugihara et al9 found patients with 
metachronous disease having a significantly better prognosis than those with 
synchronous disease in both univariate and multivariate analyses. The authors went on 
to attribute these findings in part to the lower recurrence rate in the abdominal cavity 
for metachronous patients.  
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The limitations of our study are evident with the lack off and missing data for certain 
covariates. While elevated carcinoembryonic antigen level was found to be a predictor 
of poorer outcome by several authors7, 8, 13, 16, 19, 20 this covariate was unable to be 
analysed due to the large amount of missing data (27%). Primary tumour 
differentiation, found to be predictive of poorer outcome by others3, 6, 8, 19 was unable 
to be analysed in this study as this data is not routinely collected in our department. 
The hepatic tumour differentiation is routinely collected, however, this had to be 
dropped from the final model due to missing data, caused by omission in the 
histopathology reports by the reporting histopathologists.  
 
 
Conclusion 
 
The timing of diagnosis of liver metastases from primary disease might be an 
important predictor of outcome post hepatic surgery.  While this study did not find a 
statistically significant difference in overall survival between synchronous and 
metachronous patients, it did find strong evidence of a difference in disease free 
survival between the groups. In summary, there is a need for routine PET scans at the 
time of primary surgery to correctly identify extra-hepatic disease to identify patients 
for the correct line of treatment, either chemotherapy first or straight to liver surgery. 
The effects of this need to be investigated further in larger studies with an emphasis 
on time-limited systemic chemotherapy to prevent hepatotoxicity. 
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Table 1‐ Patient Characteristics 
Variable    
Synchronous 
CLM n(%) 
Metachronous 
CLM n(%)  P‐value*  Total N(%) 
Total  138 (50)  138 (50)  276 
Demographic characteristics 
Age (yr) ‐ mean (SD)  62 (11)  66 (11)  <0.01 
Gender 
Male  85 (62)  88 (64)  0.71  173 (63) 
Female  53 (38)  50 (36)  103 (37) 
Primary resection characteristics 
Primary site 
Colon  88 (64)  98 (71)  0.2  186 (67) 
Rectum  50 (36)  40 (29)  90 (33) 
Dukes classification 
Dukes A + B  39 (29)  56 (41)  0.05  95 (35) 
Dukes C  95 (71)  82 (59)  177 (65) 
Missing  4  0  4 
Complications primary 
Yes  13 (10)  14 (10)  0.94  27 (10) 
No  116 (90)  121 (90)  237 (90) 
Missing  9  3  12 
Pre‐operative chemotherapy 
Yes  97 (70)  94 (68)  0.7  191 (69) 
No  41 (30)  44 (32)  85 (31) 
Liver resection characteristics 
Operation type 
Minor  47 (34)  61 (44)  0.08  108 (39) 
Major  91 (66)  77 (56)  168 (61) 
Operative time (mins) 
<180  43 (34)  51 (39)  0.49  94 (37) 
180‐239  41 (33)  45 (35)  86 (34) 
>=240  41 (33)  34 (26)  75 (29) 
Missing  13  8  21 
Blood loss (ml) 
<200  59 (44)  68 (51)  0.16  127 (48) 
200‐399  38 (29)  25 (19)  63 (24) 
>=400  36 (27)  41 (31)  77 (29) 
Missing  5  4  9 
Tumour site 
Unilateral  81 (59)  109 (79)  <0.01  190 (69) 
Bilateral/Central  57 (41)  29 (21)  86 (31) 
Tumour size (mm) 
0‐19  30 (22)  18 (13)  0.22  48 (17) 
20‐39  56 (41)  58 (42)  114 (41) 
40‐59  26 (19)  27 (20)  53 (19) 
>=60  26 (19)  35 (25)  61 (22) 
Tumour number 
1 tumour  51 (37)  79 (57)  <0.01  130 (47) 
2‐3 tumours  50 (36)  45 (33)  95 (34) 
>3 tumours  37 (27)  14 (10)  51 (18) 
Tumour differentiation 
Well/Moderate  102 (89)  117 (98)  <0.01  219 (93) 
Poor  13 (11)  3 (3)  16 (7) 
Missing  23  18  41 
Resection margin (mm) 
>10  32 (23)  36 (26)  0.48  68 (25) 
1‐10  64 (46)  54 (39)  118 (43) 
<1  42 (30)  48 (35)  90 (33) 
Length of stay (nights) 
0‐6  30 (22)  38 (28)  0.29  68 (25) 
7‐10  81 (59)  68 (49)  149 (54) 
>10  27 (20)  32 (23)  59 (21) 
Post‐operative complications 
None  82 (59)  78 (57)  0.09  160 (58) 
Minor  38 (28)  27 (20)  65 (24) 
Major  16 (12)  30 (22)  46 (17) 
   Mortality  2 (1)  3 (2)     5 (2) 
*P-Value reported is for a difference between Synchronous and Metachronous groups over all categories for each variable. 
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Table 2 ‐ Summary of univariate analysis performed by log‐rank test for overall and disease free survival 
Variable  n 
Median overall 
survival (mo)  HR  P‐value* 
Median 
disease free 
survival (mo)  HR  P‐value* 
Age 
0‐64  143  58 1.00 0.06 18 1.00  0.83 
>=65  133  36 1.38 13 1.03 
Gender 
Male   173  40  1.00  0.09  15  1.00  0.08 
Female  103  76  0.73  18  0.76 
Primary site 
Colon  186  48 1.00 0.51 15 1.00  0.85 
Rectum  90  43 1.13 18 1.03 
Dukes classification 
Dukes A & B  95  56  1.00  0.04  25  1.00  0.03 
Dukes C  177  39  1.48  14  1.43 
Timing 
Metachronous  138  57 1.00 0.04 24 1.00  <0.01 
Synchronous  138  36  1.42  10  1.57 
Complications primary 
Yes  27  32  1.00  0.12  11  1.00  0.08 
No  237  48  0.65  18  0.67 
Pre‐operative chemo 
Yes  191  40 1.00 0.16 13 1.00  0.03 
No  85  51  0.77  25  0.71 
Operation type 
Minor  108  N/A  1.00  <0.01  23  1.00  <0.01 
Major  168  39  1.77  12  1.74 
Blood loss (ml) 
0‐199  127  58  1.00  <0.01  23  1.00  <0.01 
200‐399  63  45  1.28  15  1.33 
>=400  77  34  1.93  10  1.73 
Length of operation 
0‐179  94  56  1.00  0.04  22  1.00  0.02 
180‐239  86  47  1.11  18  1.19 
>=240  75  34  1.66  9  1.67 
Tumour site 
Unilateral  190  51  1.00  <0.01  23  1.00  <0.01 
Bilateral/Central  86  25  1.87  7  2.07 
Tumour size 
0‐19  48  65  1.00  <0.01  20  1.00  <0.01 
20‐39  114  58  1.36  22  1.20 
40‐59  53  32  2.46  8  2.13 
>=60  61  25  2.44  14  1.58 
Tumour number 
1  130  58  1.00  <0.01  28  1.00  <0.01 
2‐3  95  33  1.52  13  1.61 
>3  51  22  2.68  6  3.31 
Tumour differentiation 
Well/Moderate  219  44  1.00  <0.01  16  1.00  <0.01 
Poor  16  19  2.35  8  2.27 
Resection margin (mm) 
>10  68  106  1.00  <0.01  24  1.00  <0.01 
1‐10  118  49 1.53 14 1.54 
<1  90  31 2.36 12 1.91 
Length of stay (nights) 
0‐6  68  106  1.00  <0.01  24  1.00  <0.01 
7‐10  149  48  1.46  18  1.40 
>=11  59  22 3.30 8 2.68 
Post‐operative complications 
Minor  225  48 1.00 0.05 18 1.00  0.15 
Major  46  39  1.54  11  1.32 
                 
___________________________________________________________________________________________________ 
*P-Value reported is for a difference between Synchronous and Metachronous groups over all categories for each variable. 
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Table 3 – Multivariate results from Cox models for both overall and disease free survival 
Overall Survival  Disease Free Survival 
Variable     HR  (95% CI)  P‐value**  HR  (95% CI)  P‐value** 
Timing 
Metachronous  1.00  1.00 
Synchronous  1.42  (0.98, 2.06)  0.06  1.47  (1.08, 2.00)  0.01 
Age 
<65  1.00  ‐ 
>=65  1.48  (1.02, 2.16)  0.04  ‐  ‐  ‐ 
Pre‐op chemo 
Yes  1.00  ‐ 
No  0.60  (0.41, 0.90)  0.01  ‐  ‐  ‐ 
Size (mm) 
<20  1.00  1.00 
20‐39  1.33  (0.70, 2.52)  0.39  1.12  (0.69, 1.81)  0.64 
40‐59  2.07  (1.06, 4.04)  0.03  2.05  (1.22, 3.47)  <0.01 
>=60  2.75  (1.41, 5.36)  <0.01  1.76  (1.05, 2.95)  0.03 
Tumour number 
1  1.00  1.00 
2‐3  1.66  (1.09, 2.53)  0.02  1.54  (1.09, 2.19)  0.02 
>3  2.39  (1.47, 3.90)  <0.01  2.74  (1.81, 4.14)  <0.01 
Primary site >3.5 yrs post hepatectomy * 
Colon  1.00  ‐ 
Rectum  2.88  (1.29, 6.40)  0.01  ‐  ‐  ‐ 
Length of stay 
0‐6  1.00  1.00 
7‐10  1.20  (0.76, 1.91)  0.43  1.27  (0.86, 1.86)  0.23 
   >=11  2.63  (1.53, 4.50)  <0.01  2.19  (1.39, 3.47)  <0.01 
* Primary site <3.5 years found to be non‐
significant 
** P‐value reported is for tests of each category against its reference category for each variable. 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
 
Figure 1: Overall survival by timing 
 
Figure 1 shows the survival curves for Overall Survival between Synchronous and Metachronous 
groups with the number of patients at risk at 20 month intervals. The box above shows the results from 
the final multivariate model for Overall Survival. 
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Figure 2: Disease free survival by timing 
 
Figure 2 shows the survival curves for Disease Free Survival between Synchronous and Metachronous 
groups with the number of patients at risk at 20 month intervals. The box above shows the results from 
the final multivariate model for Disease Free Survival. 
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Appendix 
 
Statistical considerations 
 
One of the challenges for building the survival models for Overall Survival and 
Disease Free Survival was the variable selection process incuding the categorisation 
of the variables. While analysing continuous variables as continuous variables is 
statistically preferred, it was decided to categorise these variables into two, three or 
four categories so that they are easily interpretable for clinicians. While clinicans 
prefer to use known categories, this was not always possible due to low numbers of 
events in some categories which resulted in some categories being merged such as 
Dukes A and B in the Stage variable. 
 
The analyses in this paper excluded patients who had multiple hepatic operations 
which included 40 patients who went on the have a secondary resection and three 
patient who had a third resection. While it is common to find these patients excluded 
in other papers, it may have been possible to model these patients in a recurrent event 
type model. Since I was baseing this analysis on other analyses that excluded these 
patients, I did not consider a more complex recurrent event model until the current 
analysis was underway.  
 
One of the main limitations for this analysis was the amount of missing data for 
certain variables. While the hepatic data was reasonably complete, the data for the 
primary resection was non-existent. As the colorectal department has not had a data 
manager for many years, their database is incomplete and unreliable. I was therefore 
required to obtain as much of the missing data for the analysis as possible. At one 
point multiple imputation was considered for variables with only few missing data 
such as length of stay. It was decided in the end to chase down this data by calling 
hospitals to obain these few missing data. This was not feasible for other variables 
such as CEA which would require much more effort to obtain and would most likely 
be missing for most patients anyway, thus was excluded from the model. 
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Variable selection 
 
Overall survival 
 
Variable survival was plotted to examine the adequacy of the chosen variable 
categories (Figure A1-A5). This was examined visually and also using the log-rank 
test to ensure sufficient events had occurred in each category. The violation of the 
proportional hazards assumption is evident in Figure A2 in the Primary Site plot 
where the two hazard lines cross at time equal to approximately 42 months post 
hepatic surgery. This violation was resolved by spilting the data at time equal to 42 
months and by analysing the data using the variable Primary Site as a time-varying 
covariate. 
 
Figure A1 
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Figure A2 
 
 
Figure A3 
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Figure A4 
 
 
 
Figure A5 
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Disease free survival 
 
The same method of variable selection was carried out for disease free survival as for 
overall survival. Figure A6 shows the survival by timing of hepatic metastases while 
Figure A7-A10 shows the survival by the other potential risk factors.  
Figure A6 
 
Figure A7 
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Figure A8 
 
 
 
 
Figure A9 
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Figure A10 
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Table A1: Model Building: Overall survival                     
Variable                               
Dropped Variables Step1  Step2  Step3  Step4  Step5  Step6  Step7  Step8  Step9  Step10 
0bn.bloodloss .                            
1.bloodloss 0.97    
2.bloodloss 1.06                            
0bn.optimecat .  .                         
1.optimecat 0.76  0.76    
2.optimecat 0.87  0.89                         
0bn.majoroperation .  .  .                      
1.majoroperation 1.01  1.02  0.89                      
1bn.resectionmargins .  .  .  .                   
2.resectionmargins 0.94  0.95  1.03  1.03    
3.resectionmargins 1.03  1.08  1.12  1.10                   
0bn.primarysite<3.5yrs .  .  .  .  .                
1.primarysite<3.5yrs 0.86  0.83  0.82  0.82  0.82                
1bn.sex .  .  .  .  .  .             
2.sex 0.86  0.84  0.80  0.79  0.78  0.80             
1bn.tumoursite .  .  .  .  .  .  .          
2.tumoursite 1.59  1.58  1.48  1.49  1.52  1.50  1.31          
1bn.stage .  .  .  .  .  .  .  .       
2.stage 1.23  1.24  1.35  1.35  1.35  1.38  1.41  1.41       
2bn.surgcomp .  .  .  .  .  .  .  .  .    
3.surgcomp 1.12  1.09  1.01  1.01  1.02  1.05  1.50  1.53  1.48    
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Variables kept in Model Step1  Step2  Step3  Step4  Step5  Step6  Step7  Step8  Step9  Step10 
1bn.timing .  .  .  .  .  .  .  .  .  . 
2.timing 1.30  1.31  1.32  1.33  1.34  1.31  1.36  1.43  1.52*  1.42 
0bn.agecat .  .  .  .  .  .  .  .  .  . 
1.agecat 1.53*  1.56*  1.43  1.45  1.46  1.48*  1.57*  1.53*  1.60*  1.48* 
1bn.preopchemo .  .  .  .  .  .  .  .  .  . 
2.preopchemo 0.64  0.66  0.72  0.74  0.73  0.74  0.74  0.70  0.60*  0.60* 
0bn.size .  .  .  .  .  .  .  .  .  . 
1.size 1.35  1.40  1.30  1.29  1.29  1.32  1.40  1.41  1.43  1.33 
2.size 1.87  1.87  1.84  1.82  1.87  1.91  2.06*  2.11*  2.17*  2.07* 
3.size 2.59*  2.69*  2.58*  2.52*  2.59**  2.64**  2.92**  3.04**  3.05**  2.75** 
1bn.tumournumber .  .  .  .  .  .  .  .  .  . 
2.tumournumber 1.25  1.26  1.38  1.34  1.35  1.38  1.37  1.48  1.50  1.66* 
3.tumournumber 1.68  1.75  1.99*  1.91*  1.93*  1.92*  2.31**  2.57***  2.63***  2.40*** 
0bn.primarysite>3.5yrs .  .  .  .  .  .  .  .  .  . 
1.primarysite>3.5yrs 2.45*  2.46*  2.73*  2.72*  2.73*  2.78*  2.79*  2.77*  2.73*  2.88* 
0bn.los .  .  .  .  .  .  . 
1.los 1.14  1.16  1.22  1.19  1.20  1.18  1.20 
2.los 2.56**  2.53**  2.46**  2.37**  2.41**  2.34**  2.63*** 
N 331  334  358 358 358 358  358 358 362 367
Exponentiated coefficients 
* p<0.05, ** p<0.01, *** p<0.001 
bn=Base Reference Category 
 
 
Tables A1 and A2 shows the model building process for overall survival and disease free survival respectively. The model building process for 
each started from the full model with all variables significant at the univariate analysis with P≤0.25.  Variables were removed one at a time, 
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starting with least significant and remained in model if p<0.05 or were confounded with synchronous/metachronous, indicated by more than 
10% change in HR. At the end of the process, excluded variables were also entered into the model to check for their significance and 
confounding.   
 
Table A2: Model Building: Disease free survival                  
Variable                            
Dropped Variables Step1  Step2  Step3  Step4  Step5  Step6  Step7  Step8  Step9 
0bn.optimecat .                         
1.optimecat 0.95    
2.optimecat 1.07                         
0bn.bloodloss .  .                      
1.bloodloss 0.96  0.97    
2.bloodloss 0.97  1.10                      
1bn.resectionmargins .  .  .                   
2.resectionmargins 1.12  1.12  1.17    
3.resectionmargins 0.99  0.99  1.02                   
1bn.primarysite .  .  .  .                
2.primarysite 0.91  0.90  0.88  0.88                
1bn.sex .  .  .  .  .             
2.sex 0.90  0.89  0.86  0.87  0.88             
0bn.majoroperation .  .  .  .  .  .          
1.majoroperation 0.86  0.86  0.86  0.84  0.85  0.83          
1bn.stage .  .  .  .  .  .  .       
2.stage 1.33  1.31  1.31  1.28  1.29  1.28  1.27       
1bn.tumoursite .  .  .  .  .  .  .  .    
2.tumoursite 1.43  1.40  1.38  1.37  1.36  1.35  1.35  1.41    
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Variables kept in Model Step1  Step2  Step3  Step4  Step5  Step6  Step7  Step8  Step9 
1bn.timing .  .  .  .  .  .  .  .  . 
2.timing 1.38  1.33  1.40*  1.42*  1.40*  1.39*  1.39*  1.42*  1.47* 
1bn.preopchemo .  .  .  .  .  .  .  .  . 
2.preopchemo 0.72  0.74  0.73  0.73  0.73  0.72  0.74  0.69*  0.66* 
0bn.size .  .  .  .  .  .  .  .  . 
1.size 1.08  1.11  1.15  1.16  1.18  1.17  1.15  1.11  1.12 
2.size 1.88*  2.09*  2.11**  2.10**  2.12**  2.13**  2.05**  1.96*  2.05** 
3.size 1.87*  2.02*  2.01*  2.02*  2.07**  2.07**  1.94*  1.75*  1.76* 
1bn.tumournumber .  .  .  .  .  .  .  .  . 
2.tumournumber 1.29  1.43  1.42  1.47  1.49*  1.49*  1.42  1.40  1.54* 
3.tumournumber 2.26**  2.51*** 2.59*** 2.67***  2.63***  2.69***  2.47***  2.30***  2.74*** 
0bn.los .  .  .  .  .  .  .  .  . 
1.los 1.42  1.32  1.35  1.31  1.30  1.35  1.30  1.27  1.27 
2.los 2.68***  2.51*** 2.45*** 2.40***  2.39***  2.48***  2.34***  2.30***  2.19*** 
N  248  263  272  272  272  272  272  276  276 
Exponentiated coefficients 
* p<0.05, ** p<0.01, *** p<0.001 
bn=Base Reference Category 
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Diagnostics 
 
Overall survival 
 
The final model for Overall Survival was assessed for validity of proportional hazards 
assumption using Shoenfeld residuals and goodness of fit using Cox-Snell residuals 
(see Table A3 and Figure A11). The proportional hazards assumption is not violated 
and the goodness of fit appears adequate 
 
Table A3: Proportional hazards assumption (Overall Survival) 
 
Variable  rho  chi2  df  Prob>chi2
0b.agecat  .  .  1  . 
1.agecat  ‐0.08  0.92  1  0.34 
1.timing  0.00  0  1  0.98 
2b.timing  .  .  1  . 
1b.preopchemo  .  .  1  . 
2.preopchemo  0.07  0.74  1  0.39 
0b.tumoursize  .  .  1  . 
1.tumoursize  ‐0.02  0.05  1  0.82 
2.tumoursize  ‐0.01  0  1  0.95 
3.tumoursize  ‐0.13  2.36  1  0.12 
1b.tumourno  .  .  1  . 
2.tumourno  ‐0.15  3.03  1  0.08 
3.tumourno  ‐0.09  1.18  1  0.28 
0b.primarysite>3.5yrs  .  .  1  . 
1.primarysite>3.5yrs  ‐0.08  0.81  1  0.37 
0b.los  .  .  1  . 
1.los  ‐0.02  0.06  1  0.80 
2.los  0.08  0.81  1  0.37 
Global Test     10.76  11  0.46 
b=Base Reference Category 
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Figure A11 
 
 
 
Disease free survival 
 
The final model for Disease Free Survival was assessed for validity of proportional 
hazards assumption using Shoenfeld residuals and goodness of fit using Cox-Snell 
residuals (see Table A4 and Figure A12). The proportional hazards assumption is not 
violated and the goodness of fit appears adequate. 
 
Table A4: Proportional hazards assumption (Disease Free Survival) 
 
Variable  rho  chi2  df  Prob>chi2
1.timing  ‐0.05  0.43  1  0.51 
2b.timing  .  .  1  . 
1b.preopchemo  .  .  1  . 
2.preopchemo  0.01  0.02  1  0.90 
0b.size  .  .  1  . 
1.size  0.07  0.8  1  0.37 
2.size  0.10  1.78  1  0.18 
3.size  0.06  0.56  1  0.45 
1b.tumourno  .  .  1  . 
2.tumourno  ‐0.07  0.95  1  0.33 
3.tumourno  ‐0.07  0.99  1  0.32 
0b.los  .  .  1  . 
1.los  0.04  0.23  1  0.63 
2.los  0.04  0.3  1  0.58 
Global Test     4.39  9  0.88 
b=Base Reference Category 
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Figure A12 
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